Mouse models of human neurodegenerative disorders: Requirements for medication development

Floyd E. Bloom, John F. Reilly, Jeff M. Redwine, Chi Cheng Wu, Warren G. Young, John Morrison

Research output: Contribution to journalReview article

24 Citations (Scopus)

Abstract

Central nervous system diseases constitute a major target for drug development. Transgenic mouse models, in which genes identified in familial forms of human brain diseases are expressed in mouse neurons and glia, offer opportunities to detect and follow pathologic progression and provide potential biomarkers by which to assess therapeutic interventions. Evidence for Alzheimer disease suggests some starting requirements for the experimental data that could enhance the likelihood of developing medications in these mouse models that would also be effective in humans.

Original languageEnglish (US)
Pages (from-to)185-187
Number of pages3
JournalArchives of Neurology
Volume62
Issue number2
DOIs
StatePublished - Feb 1 2005
Externally publishedYes

Fingerprint

Neurodegenerative Diseases
Central Nervous System Diseases
Brain Diseases
Neuroglia
Transgenic Mice
Alzheimer Disease
Biomarkers
Neurons
Pharmaceutical Preparations
Genes
Medication
Mouse
Therapeutics
Central Nervous System
Alzheimer's Disease
Familial
Drugs
Progression
Gene
Neuron

ASJC Scopus subject areas

  • Arts and Humanities (miscellaneous)
  • Clinical Neurology

Cite this

Mouse models of human neurodegenerative disorders : Requirements for medication development. / Bloom, Floyd E.; Reilly, John F.; Redwine, Jeff M.; Wu, Chi Cheng; Young, Warren G.; Morrison, John.

In: Archives of Neurology, Vol. 62, No. 2, 01.02.2005, p. 185-187.

Research output: Contribution to journalReview article

Bloom, Floyd E. ; Reilly, John F. ; Redwine, Jeff M. ; Wu, Chi Cheng ; Young, Warren G. ; Morrison, John. / Mouse models of human neurodegenerative disorders : Requirements for medication development. In: Archives of Neurology. 2005 ; Vol. 62, No. 2. pp. 185-187.
@article{138958ce85034417916f7ae70a06fdde,
title = "Mouse models of human neurodegenerative disorders: Requirements for medication development",
abstract = "Central nervous system diseases constitute a major target for drug development. Transgenic mouse models, in which genes identified in familial forms of human brain diseases are expressed in mouse neurons and glia, offer opportunities to detect and follow pathologic progression and provide potential biomarkers by which to assess therapeutic interventions. Evidence for Alzheimer disease suggests some starting requirements for the experimental data that could enhance the likelihood of developing medications in these mouse models that would also be effective in humans.",
author = "Bloom, {Floyd E.} and Reilly, {John F.} and Redwine, {Jeff M.} and Wu, {Chi Cheng} and Young, {Warren G.} and John Morrison",
year = "2005",
month = "2",
day = "1",
doi = "10.1001/archneur.62.2.185",
language = "English (US)",
volume = "62",
pages = "185--187",
journal = "Archives of Neurology",
issn = "0003-9942",
publisher = "American Medical Association",
number = "2",

}

TY - JOUR

T1 - Mouse models of human neurodegenerative disorders

T2 - Requirements for medication development

AU - Bloom, Floyd E.

AU - Reilly, John F.

AU - Redwine, Jeff M.

AU - Wu, Chi Cheng

AU - Young, Warren G.

AU - Morrison, John

PY - 2005/2/1

Y1 - 2005/2/1

N2 - Central nervous system diseases constitute a major target for drug development. Transgenic mouse models, in which genes identified in familial forms of human brain diseases are expressed in mouse neurons and glia, offer opportunities to detect and follow pathologic progression and provide potential biomarkers by which to assess therapeutic interventions. Evidence for Alzheimer disease suggests some starting requirements for the experimental data that could enhance the likelihood of developing medications in these mouse models that would also be effective in humans.

AB - Central nervous system diseases constitute a major target for drug development. Transgenic mouse models, in which genes identified in familial forms of human brain diseases are expressed in mouse neurons and glia, offer opportunities to detect and follow pathologic progression and provide potential biomarkers by which to assess therapeutic interventions. Evidence for Alzheimer disease suggests some starting requirements for the experimental data that could enhance the likelihood of developing medications in these mouse models that would also be effective in humans.

UR - http://www.scopus.com/inward/record.url?scp=13444301296&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=13444301296&partnerID=8YFLogxK

U2 - 10.1001/archneur.62.2.185

DO - 10.1001/archneur.62.2.185

M3 - Review article

C2 - 15710845

AN - SCOPUS:13444301296

VL - 62

SP - 185

EP - 187

JO - Archives of Neurology

JF - Archives of Neurology

SN - 0003-9942

IS - 2

ER -